Suppr超能文献

门诊小儿水痘感染患者抗生素使用的临床和经济负担:法国真实世界数据的回顾性队列分析。

Clinical and Economic Burden of Antibiotic Use Among Pediatric Patients With Varicella Infection in the Outpatient Setting: A Retrospective Cohort Analysis of Real-world Data in France.

机构信息

From the Center for Observational and Real-world Evidence, Merck & Co., Inc., Rahway, New Jersey.

Adelphi Real World, Bollington, United Kingdom.

出版信息

Pediatr Infect Dis J. 2024 Apr 1;43(4):393-399. doi: 10.1097/INF.0000000000004254. Epub 2024 Feb 16.

Abstract

BACKGROUND

Varicella infects 90% of children before age 9. Though varicella is self-limiting, its complications may require antibiotics, though how antibiotics are utilized for varicella in France is not well known. This study assessed antibiotic use and costs associated with varicella and its complications in pediatric patients managed in the outpatient setting in France.

METHODS

A retrospective cohort study using the Cegedim Strategic Data-Longitudinal Patient Database, an electronic medical record database from general practitioners and office-based specialists in France, was conducted. Children <18 years old diagnosed with varicella between January 2014 and December 2018 with 3-month follow-up available were included. We used descriptive analysis to assess varicella-related complications, medication use, healthcare resource utilization and costs.

RESULTS

Overall, 48,027 patients were diagnosed with varicella; 15.3% (n = 7369) had ≥1 varicella-related complication. Antibiotics were prescribed in up to 25.1% (n = 12,045/48,027) of cases with greater use in patients with complications (68.1%, n = 5018/7369) compared with those without (17.3%, n = 7027/40,658). Mean medication and outpatient varicella-related costs were €32.82 per patient with medications costing a mean of €5.84 per patient; antibiotics contributed ~23% to total costs annually.

CONCLUSION

This study showed high antibiotic use for the management of varicella and its complications. A universal varicella vaccination program could be considered to alleviate complications and associated costs in France.

摘要

背景

水痘在 9 岁前感染了 90%的儿童。虽然水痘是自限性的,但它的并发症可能需要使用抗生素,尽管法国对水痘使用抗生素的情况尚不清楚。本研究评估了法国门诊环境中管理的儿科患者中与水痘及其并发症相关的抗生素使用情况和费用。

方法

使用 Cegedim 战略数据-纵向患者数据库进行回顾性队列研究,该数据库是法国全科医生和专科医生的电子病历数据库。纳入 2014 年 1 月至 2018 年 12 月期间诊断为水痘且有 3 个月随访的<18 岁儿童。我们使用描述性分析评估水痘相关并发症、药物使用、医疗资源利用和费用。

结果

共有 48027 例患者被诊断为水痘,15.3%(n=7369)有≥1 种水痘相关并发症。在有并发症的患者中(68.1%,n=5018/7369),抗生素的使用率高达 25.1%(n=12045/48027),而无并发症的患者(17.3%,n=7027/40658)抗生素的使用率较低。每位患者的药物和门诊水痘相关费用平均为 32.82 欧元,每位患者的药物费用平均为 5.84 欧元;抗生素每年约占总费用的 23%。

结论

本研究表明,法国在管理水痘及其并发症时抗生素的使用量较高。可以考虑实施普遍的水痘疫苗接种计划,以减轻法国的并发症和相关费用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7717/10919277/639e8d1cb57f/inf-43-0393-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验